WHO Pharmaceuticals Newsletter 2003, No. 03
(2003; 14 pages) Ver el documento en el formato PDF
Índice de contenido
Abrir esta carpeta y ver su contenidoREGULATORY MATTERS
Cerrar esta carpetaSAFETY OF MEDICINES
Ver el documentoANTIRETRO-VIRALS - Benefit/Risk balance remains strongly positive for combination antiretroviral therapy
Ver el documentoCYPROTERONE ACETATE & ETHINYL-ESTRADIOL - Update on risk of venous thromboembolism
Ver el documentoDIETHYL-STILBESTROL - Gynaecological and obstetric complications after in utero exposure
Ver el documentoEPHEDRA - Moves to reduce risks of ephedra-containing products
Ver el documentoFLUTICASONE PROPIONATE - Reports of adrenal crisis
Ver el documentoGRAPEFRUIT JUICE - Revised advice from ADRAC
Ver el documentoHORMONE REPLACEMENT THERAPY (HRT) - Risk of dementia
Ver el documentoOMEPRAZOLE, RABEPRAZOLE - Reports of interstitial nephritis
Ver el documentoROFECOXIB, CELECOXIB - Case reports support causal association with liver toxicity
Ver el documentoROSIGLITA-ZONE, PIOGLITAZONE - Adverse reactions update
Ver el documentoSOMATROPIN - Not to be authorized for AIDS-related wasting syndrome
Abrir esta carpeta y ver su contenidoCURRENT CONCERNS
Abrir esta carpeta y ver su contenidoDRUGS OF INTEREST
Abrir esta carpeta y ver su contenidoFEATURE
 

EPHEDRA - Moves to reduce risks of ephedra-containing products

USA. In the US, the Department of Health and Human Services (HHS) has announced plans to take action regarding the potentially serious risks associated with ephedra-containing dietary products. Ephedra is a naturally occurring substance derived from the Chinese herbal Ma Huang. It is an adrenaline-like stimulant that can have potentially dangerous effects on the nervous system and heart. On the basis of new evidence in the medical literature and in adverse event reports, there are reasons for the heightened concern that dietary supplements containing ephedra may present a significant and unreasonable risk of illness and injury.

Under the Dietary Supplement Health and Education Act of 1994, FDA does not review dietary supplements for safety and efficacy before they are marketed but the law allows the FDA to prohibit the sale of a dietary supplement if it ‘presents a significant or unreasonable risk’. In order to assess these risks, the HHS and FDA will

• seek rapid pubic comment on the new evidence on health risks associated with ephedra

• seek rapid public comment on whether the currently available evidence presents a ‘significant or unreasonable risk of illness or injury’

• seek rapid public comment on a strong new warning label for ephedra products

• immediately execute a series of actions against ephedra products making unsubstantiated claims.


The American Heart Association has also called for a ban on ephedra-containing products in comments submitted to the US FDA. The Association supports the FDA's proposal to limit the manufacturing and marketing of ephedra-based supplements, but believes these products should be completely banned. The president of the American Heart Association, Dr Robert O. Bonow, says that there is growing evidence that the risks of ephedra-containing supplements, which are primarily cardiovascular, far outweigh any potential benefit, and because patients have a tendency to ignore warning labels and dosage information, a complete ban is necessary to eliminate the risks

Reference:

1. Department of Health and Human Services Media Release: 28 Feb 2003. Available from URL: http://www.fda.gov

2. American Heart Association Media Release, 3 Apr 2003. Available from URL http://www.americanheart.org

Ir a la sección anterior
Ir a la siguiente sección
 
 
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 1 diciembre 2019